Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-05

Study Completion Date

2024-09-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of fatty liver disease (NAFLD: Non-Alcoholic Fatty Liver Disease or to a more severe degree NASH: Non-Alcoholic SteatoHepatitis) reached 40-70% in subjects with type 2 diabetes (T2D). NAFLD can be easily detected by performing a hepatic ultrasonography. The presence of a NAFLD is positively correlated with the severity of insulin resistance and dysglycemia in this population. The presence of NAFLD worsens the prognosis of T2D with an increased cardiovascular risk. This hepatic impairment would also increase the risk of microvascular complications, especially nephropathy. Conversely, T2D increases the risk of transition from NAFLD to NASH and then to hepatic fibrosis and its related complications (cirrhosis, hepatocellular carcinoma). The risk of progression of liver steatosis to fibrosis is also more important as diabetes and insulin resistance are more severe.

In addition to diabetes and insulin resistance, other risk factors are associated with more severe liver damage such as changes in microbiota. Indeed, it has already been described a smaller amount of bacteroides in the microbiota of subjects with T2D and the most severe hepatic impairment. The treatment of NAFLD/NASH is poorly codified without approved drugs in this indication, while many phase 3 trials with candidate drugs are undergoing. Life-style measures (physical activity and low carbohydrate/calorie diet) can limit the progression from NAFLD to more severe liver fibrosis. Some bariatric surgery studies have also shown good results in this situation. Pharmacological interventions are also reported with proven efficacy of pioglitazone, vitamin E and orlistat.

The OPT2MISE study has recently shown the superiority of insulin pump (or continuous sub-cutaneous insulin infusion: CSII) compared to multiple daily insulin injections (MDI) to improve glycemic control in a population of patients with T2D in failure of well-titrated MDI. In addition, treatment with CSII showed a 45% decrease in insulin resistance (assessed by HOMA-IR) in a population of newly diagnosed T2D.

In light of these data, investigators hypothesize that the introduction of insulin pump treatment in a population of subjects with T2D and NAFLD, by improving insulin sensitivity, could reduce fatty liver content compared to standard MDI treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Avoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics

NCT06782568

Type 1 Diabetes (T1D) Type 2 Diabetes, Insulin Requiring

NOT_YET_RECRUITING NA

Hepatic and Cardiac Metabolic Flexibility in Subjects With T2DM With and Without NAFLD

NCT04698486

NAFLD - Non-Alcoholic Fatty Liver Disease Type 2 Diabetes

COMPLETED NA

Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

NCT01674972

Non Alcoholic Fatty Liver Disease Non Alcoholic Steatohepatitis

COMPLETED

Combined Active Treatment in Type 2 Diabetes with NASH

NCT04639414

Type 2 Diabetes Non-alcoholic Steatohepatitis (NASH) Non-alcoholic Fatty Liver Disease (NAFLD)

ACTIVE_NOT_RECRUITING PHASE4

Glucagon Resistance in Patients With NAFLD

NCT04042142

Non-Alcoholic Fatty Liver Disease Non-alcoholic Steatohepatitis Glucose Metabolism Disorders

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes (T2D)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)

Intervention Type PROCEDURE

Multi-injection treatment ( MDI ).

Corresponds to an outpatient visit if the patient is randomized into the multi-injection group

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male / female 35/70 years (including ranges) with T2D ≥ 1 year
* Benefiting from the indication of use of the free Freestyle glucose meter
* Treatment with multi-injection insulin therapy comprising a daily injection of basal insulin (Glargine U100, Glargine U300, Degludec) and at least 2 daily injections of an insulin analogue (lispro, aspart or glulisine) +/- metformin, dipeptidyl peptidase-4 (DPP4) and/or sodium-glucose cotransporter type 2 (SGLT2) at a dose stable for at least 3 months.
* For women of childbearing age, oestro-progestative pill, IUD, implant.
* 11% ≥ HbA1c ≥ 6.5%
* Presence of hepatic steatosis according to the ultrasonography
* Absence of chronic alcoholic intoxication
* Absence of chronic viral hepatitis or other chronic liver diseases (eg hemochromatosis ...)

Exclusion Criteria

* Type 1 diabetes
* Contraindication to pump treatment
* Treatment with anti-diabetics or other than metformin, dipeptidyl peptidase-4 (DPP4) and/or sodium-glucose cotransporter type 2 (SGLT2)
* Treatment with basal inulin of Levemir
* Contraindication to performing MRI
* Chronic alcohol abuse (after alcohol consumption\> 20g / day in men and\> 10g / day in women) according to the medical examination
* Chronic viral hepatitis based on HBV and HCV serology results
* Hemochromatosis according to the martial assessment
* Other toxic or drug hepatitis
* Severe hepatic pathology: hepatic cirrhosis, hepatocellular carcinoma
* Severe renal insufficiency (MDRD \<30 ml / min)
* Severe and progressive cardiovascular pathology
* Treatment (permanent or intermittent) with glucocorticoids
* Treatment known to improve hepatic steatosis (glitazone, vitamin E, orlistat)
* history or bariatric surgery project for the duration of the study
* Drug treatment likely to cause hepatic steatosis (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retroviral drugs) unless the dose has been stable for ≥ 3 months
* Guardianship, curatorship or safeguard of justice

Minimum Eligible Age

37 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No